GlassScriptPhysician profile
Clarissa Drogosch
NPI 1598463549
$6,659.73
in general payments reported to CMS, 2019-2025
37 companies · $2,453 in 2025
The $2,453 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,958 · 2024: $2,249 · 2025: $2,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,648 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,648.44 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,163.46 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $760.69 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Tandem Diabetes Care, INC. | $655.21 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $361.68 | 2024-2025 | Tepezza, Evenity |
| Dexcom, INC. | $349.45 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $307.30 | 2023-2025 | |
| Insulet Corporation | $288.83 | 2023-2024 | Omnipod |
| Beta Bionics, INC. | $246.72 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Corcept Therapeutics | $241.68 | 2023-2025 | Korlym |
| Abbott Laboratories | $241.42 | 2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $240.20 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $202.88 | 2023-2025 | Tymlos |
| Sequel Med Tech, LLC | $182.84 | 2025 | Twiist |
| Madrigal Pharmaceuticals | $182.13 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $161.68 | 2023-2025 | Qutenza |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $106.36 | 2025 | |
| Amneal Pharmaceuticals LLC | $101.09 | 2023-2024 | Unithroid |
| Ascensia Diabetes Care US INC. | $83.68 | 2023-2024 | |
| Abbvie INC. | $79.72 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.57 | 2023-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $77.03 | 2023-2025 | |
| Embecta Corp. | $76.63 | 2024 | Bd Nano 2nd Gen Pen Needle |
| Alexion Pharmaceuticals, INC. | $61.84 | 2023-2024 | Strensiq |
| Amphastar Pharmaceuticals, INC. | $53.61 | 2024-2025 | |
| Kyowa Kirin, INC. | $52.58 | 2023-2025 | Crysvita |
| Verity Pharmaceuticals INC. | $50.57 | 2024 | Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.14 | 2023-2024 | Cycloset |
| Ascendis Pharma Endocrinology INC | $28.51 | 2023 | |
| Acella Pharmaceuticals, LLC | $27.42 | 2024-2025 | NP Thyroid 60 |
| Amryt Pharma Holdings LTD | $26.59 | 2023 | Myalept, Mycapssa |
| Cequr Corporation | $26.48 | 2023 | Cequr Simplicity |
| Astellas Pharma US INC | $18.45 | 2024 | Veozah |
| Theracosbio, LLC | $17.22 | 2024 | Brenzavvy |
| Horizon Therapeutics Plc | $16.69 | 2023 | Tepezza |
| Nevro Corp. | $15.46 | 2023 | Senza |
| Silk Road Medical, INC. | $14.47 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Ionis Pharmaceuticals, INC. | $14.45 | 2025 | Tryngolza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clarissa Drogosch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.